Investigating immune and metabolic factors in early cardiovascular disease
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
National University Hospital, Singapore · NCT06211868
This study is testing if using digital wearables and AI-driven lifestyle changes can help people with early cardiovascular disease improve their heart health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 40 Years to 70 Years |
| Sex | All |
| Sponsor | National University Hospital, Singapore (other) |
| Locations | 1 site (Singapore) |
| Trial ID | NCT06211868 on ClinicalTrials.gov |
What this trial studies
Project RESET is a collaborative initiative in Singapore that aims to explore the immune, lipid, and metabolic factors contributing to early cardiovascular disease. The study involves a nationwide network of researchers and clinicians who will utilize a combination of digital wearables and AI-assisted lifestyle interventions to potentially halt or reverse disease progression. Participants will be monitored and assessed for their cardiovascular health while engaging in this innovative intervention. The study also includes nested randomized controlled trials to evaluate the effectiveness of these approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 40-70 with an atherosclerotic cardiovascular disease score of 5% or higher.
Not a fit: Patients with a history of major cardiovascular events or those with limited life expectancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new strategies for preventing or reversing early cardiovascular disease.
How similar studies have performed: Other studies have shown promise in using digital health interventions for cardiovascular disease management, suggesting potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 40-70 years old * ASCVD (atherosclerotic cardiovascular disease) score of 5% and higher Exclusion Criteria: * Previous major cardiovascular disease (myocardial infarction, heart failure, ischemic stroke) * Limited life expectancy * Other ongoing unstable medical conditions * Pregnant women
Where this trial is running
Singapore
- NUS — Singapore, Singapore (RECRUITING)
Study contacts
- Study coordinator: Hayang Yang, PhD
- Email: h.yang@nus.edu.sg
- Phone: +6582810448
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cardiovascular Diseases, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease